Moberg Pharma AB (publ) (MOB.ST)
SEK 11.28
(10.37%)
SEK 11.28
(10.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 27.46 Million SEK | 32.52% |
| 2022 | 20.72 Million SEK | 6.16% |
| 2021 | 19.52 Million SEK | -9.98% |
| 2020 | 21.68 Million SEK | 0.0% |
| 2018 | 279.84 Million SEK | 1.18% |
| 2017 | 276.58 Million SEK | 27.0% |
| 2016 | 217.78 Million SEK | 18.38% |
| 2015 | 183.96 Million SEK | 32.21% |
| 2014 | 139.15 Million SEK | 5.65% |
| 2013 | 131.71 Million SEK | 73.06% |
| 2012 | 76.1 Million SEK | 62.23% |
| 2011 | 46.91 Million SEK | 31.1% |
| 2010 | 35.78 Million SEK | 38.19% |
| 2009 | 25.89 Million SEK | -29.45% |
| 2008 | 36.7 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 8.15 Million SEK | -2.8% |
| 2024 Q1 | 8.38 Million SEK | 1.9% |
| 2023 Q3 | 7.26 Million SEK | 37.16% |
| 2023 Q1 | 6.67 Million SEK | 36.46% |
| 2023 FY | 26.41 Million SEK | 27.48% |
| 2023 Q2 | 5.29 Million SEK | -20.67% |
| 2023 Q4 | 8.23 Million SEK | 13.37% |
| 2022 Q2 | 4.94 Million SEK | -8.84% |
| 2022 Q1 | 5.42 Million SEK | 15.81% |
| 2022 FY | 20.72 Million SEK | 6.16% |
| 2022 Q3 | 5.47 Million SEK | 10.7% |
| 2022 Q4 | 4.89 Million SEK | -10.62% |
| 2021 FY | 19.52 Million SEK | -9.98% |
| 2021 Q4 | 4.68 Million SEK | 0.6% |
| 2021 Q1 | 6.06 Million SEK | 1.66% |
| 2021 Q2 | 4.11 Million SEK | -32.12% |
| 2021 Q3 | 4.65 Million SEK | 12.96% |
| 2020 FY | 21.68 Million SEK | 0.0% |
| 2020 Q1 | 4.21 Million SEK | -43.56% |
| 2020 Q4 | 5.96 Million SEK | 15.01% |
| 2020 Q2 | 6.31 Million SEK | 49.82% |
| 2020 Q3 | 5.19 Million SEK | -17.78% |
| 2019 Q4 | 7.46 Million SEK | 23.13% |
| 2019 Q1 | 10.6 Million SEK | -82.45% |
| 2019 Q3 | 6.06 Million SEK | -33.9% |
| 2019 Q2 | 9.17 Million SEK | -13.5% |
| 2018 Q2 | 94.16 Million SEK | 72.12% |
| 2018 FY | 279.84 Million SEK | 1.18% |
| 2018 Q4 | 60.39 Million SEK | -14.43% |
| 2018 Q3 | 70.57 Million SEK | -25.04% |
| 2018 Q1 | 54.7 Million SEK | -11.07% |
| 2017 Q3 | 50.38 Million SEK | -48.98% |
| 2017 FY | 276.58 Million SEK | 27.0% |
| 2017 Q1 | 65.93 Million SEK | -34.6% |
| 2017 Q4 | 61.52 Million SEK | 22.1% |
| 2017 Q2 | 98.75 Million SEK | 49.78% |
| 2016 FY | 217.78 Million SEK | 18.38% |
| 2016 Q1 | 48.34 Million SEK | 17.46% |
| 2016 Q2 | 19.97 Million SEK | -58.69% |
| 2016 Q3 | 48.65 Million SEK | 143.64% |
| 2016 Q4 | 100.81 Million SEK | 107.21% |
| 2015 FY | 183.96 Million SEK | 32.21% |
| 2015 Q1 | 41.85 Million SEK | 15.95% |
| 2015 Q3 | 37.72 Million SEK | -40.32% |
| 2015 Q2 | 63.22 Million SEK | 51.06% |
| 2015 Q4 | 41.16 Million SEK | 9.1% |
| 2014 Q4 | 36.09 Million SEK | 16.91% |
| 2014 Q2 | 39.95 Million SEK | 23.98% |
| 2014 Q1 | 32.22 Million SEK | 20.79% |
| 2014 FY | 139.15 Million SEK | 5.65% |
| 2014 Q3 | 30.87 Million SEK | -22.73% |
| 2013 FY | 131.71 Million SEK | 73.06% |
| 2013 Q4 | 26.68 Million SEK | -17.6% |
| 2013 Q3 | 32.37 Million SEK | -26.01% |
| 2013 Q2 | 43.75 Million SEK | 50.37% |
| 2013 Q1 | 29.09 Million SEK | 23.39% |
| 2012 Q2 | 16.72 Million SEK | -4.42% |
| 2012 Q1 | 17.49 Million SEK | 37.8% |
| 2012 FY | 76.1 Million SEK | 62.23% |
| 2012 Q4 | 23.58 Million SEK | 37.07% |
| 2012 Q3 | 17.2 Million SEK | 2.89% |
| 2011 Q2 | 13.33 Million SEK | 45.69% |
| 2011 Q4 | 12.69 Million SEK | 8.22% |
| 2011 Q3 | 11.73 Million SEK | -12.02% |
| 2011 Q1 | 9.15 Million SEK | -25.45% |
| 2011 FY | 46.91 Million SEK | 31.1% |
| 2010 Q1 | 5.31 Million SEK | 0.0% |
| 2010 FY | 35.78 Million SEK | 38.19% |
| 2010 Q3 | 9.99 Million SEK | 21.82% |
| 2010 Q4 | 12.27 Million SEK | 22.86% |
| 2010 Q2 | 8.2 Million SEK | 54.47% |
| 2009 FY | 25.89 Million SEK | -29.45% |
| 2008 FY | 36.7 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -107.284% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | 28.224% |
| BioGaia AB (publ) | 507.08 Million SEK | 94.584% |
| Enzymatica AB (publ) | 79.92 Million SEK | 65.639% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | 28.156% |
| Gabather AB (publ) | 9.47 Million SEK | -189.878% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -84.514% |
| Nanexa AB (publ) | 135.78 Million SEK | 79.774% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | 8.794% |
| ODI Pharma AB | -5.00 SEK | 549260100.0% |
| Orexo AB (publ) | 659.4 Million SEK | 95.835% |
| Probi AB (publ) | 208.93 Million SEK | 86.856% |
| Swedencare AB (publ) | 1.12 Billion SEK | 97.565% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 99.708% |
| Toleranzia AB | 6.97 Million SEK | -293.904% |
| Vivesto AB | 355.71 Million SEK | 92.28% |